Mushumba, H
Food & Drug Administration, FDA Approves New Medication for Chronic Weight Management, November 2023 6 PBS, The many ways new weight loss drugs could transform the economy, June 2024 7 MarketWatch, Obesity drugs next wave: These companies could snag 20% of GLP-1 market, analysts say, August 2024 8 The Minnesota Star Tribune, Analysis finds that after 2 years GLP-1 drugs for weight loss dont justify their price, October 2024 9 PWC, From molecules to milestones: Reinventing for the future of weight loss drugs, October 2024 10 Kaiser Family Foundation KFF Health Tracking Poll, May 2024: The Publics Use and Views of GLP-1 Drugs, Accessed: 01-13-2025 11 The Washington Post, Weight-loss drugs change shopping habits, September 2024 12 Cornell, The No-Hunger Games: How GLP-1 Medicine Adoption is Changing Consumer Food Purchases, December 2024 13 Bloomberg, Ozempic is Making People Buy Less Food, Walmart Says, October 2023
It is generally used to treat megaloblastic anemia, and peripheral neuropathies caused by vitamin b12 deficiency
With its unique pharmacology and impressive clinical data, CT-388 may soon emerge as an essential option in the landscape of metabolic diseases
